Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Blaha M ^a   Vlckova H ^b   Novakova L ^b   Solichova D ^a   Solich, P ^b   Lanska M ^a   Maly J ^a   Blaha V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

APHERESIS; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEMORHEOPHERESIS; HUMAN; IMMUNOADSORPTION; MALE; MASS SPECTROMETRY; PRESCHOOL CHILD; SCHOOL CHILD; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADULT; BLOOD; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERLIPOPROTEINEMIA TYPE 2; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; TANDEM MASS SPECTROMETRY;

ADULT; ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEMOFILTRATION; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; STATISTICS, NONPARAMETRIC; TANDEM MASS SPECTROMETRY;

EID: 78650753343     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/912472     Document Type: Article

References (42)

1. Thompsen J., Thompson P. D., A systematic review of LDL apheresis in the treatment of cardiovascular disease Atherosclerosis 2006 189 1 31 38
2. Borberg H., Quo vadis haemapheresis: current developments in haemapheresis Transfusion and Apheresis Science 2006 34 1 51 73
3. Borberg H., 26 Years of LDLapheresis: a review of experience Transfusion and Apheresis Science 2009 41 1 49 59
4. Thompson G. R., LDL apheresis Atherosclerosis 2003 167 1 1 13
5. Thompson G. R., Recommendations for the use of LDL apheresis Atherosclerosis 2008 198 2 247 255
6. Klingel R., Fassbender T., Fassbender C., Ghlen B., From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis Therapeutic Apheresis 2003 7 3 350 358
7. Wlodarczyk J., Sullivan D., Smith M., Comparison of benefits and risk sof rosuvastatin versus atorvastatin from a meta-analysis of head-tohead randomized controlled trials American Journal of Cardiology 2008 102 12 1654 1662
8. Yang D.-J., Hwang L. S., Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea Journal of Chromatography A 2006 1119 1-2 277 284
9. Blha V., Solichov D., Zadk Z., Imunoadsorption LDL-apheresis in the treatment of hypercholesterolemia: five years of research and clinical experience Nutrition 2002 18 211
10. Lins R. L., Matthys K. E., Verpooten G. A., Peeters P. C., Dratwa M., Stolear J. -C., Lameire N. H., Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients Nephrology Dialysis Transplantation 2003 18 5 967 976
11. Bellosta S., Paoletti R., Corsini A., Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 2004 109 23 50 57
12. Shitara Y., Sugiyama Y., Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacology and Therapeutics 2006 112 1 71 105
13. M. Sacks F., The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials American Journal of Cardiology 2001 88 12A 14N 18N
14. Bertolini S., Bon G. B., Campbell L. M., Farnier M., Langan J., Mahla G., Pauciullo P., Sirtori C., Egros F., Fayyad R., Nawrocki J. W., Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia Atherosclerosis 1997 130 1-2 191 197 (Pubitemid 27191040)
15. Horacek J. M., Tichy M., Pudil R., Jebavy L., Zak P., Ulrychova M., Slovacek L., Maly J., Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation Neoplasma 2008 55 6 532 537
16. Horacek J. M., Tichy M., Pudil R., Jebavy L., Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity Annals of Oncology 2008 19 9 1656 1657
17. mahelov A., Hypler R., Haas T., Tich A., Blha V., Zadk Z., Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease Pharmacological Research 2005 51 1 31 36
18. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Ueda Y., Suzuki T., Ueda S., Fukami K., Okuda S., Yamagishi S. -i., Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner Pharmacological Research 2010 61 1 58 61
19. Pastorini E., Rotini R., Guardigli M., Vecchiotti S., Persiani S., Trisolino G., Antonioli D., Rovati L. C., Roda A., Development and validation of a HPLC-ES-MS/MS method for the determination of glucosamine in human synovial fluid Journal of Pharmaceutical and Biomedical Analysis 2009 50 5 1009 1014
20. Lindegardh N., Tarning J., Toi P. V., Hien T. T., Farrar J., Singhasivanon P., White N. J., Ashton M., Day N. P. J., Quantification of artemisinin in human plasma using liquid chromatography coupled to tandem mass spectrometry Journal of Pharmaceutical and Biomedical Analysis 2009 49 3 768 773
21. Bullen W. W., Miller R. A., Hayes R. N., Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma Journal of the American Society for Mass Spectrometry 1999 10 1 55 66
22. Lee J.-H., Woo Y.-A., Hwang I.-C., Kim C.-Y., Kim D.-D., Shim C.-K., Chung S.-J., Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies Journal of Pharmaceutical and Biomedical Analysis 2009 50 5 872 877
23. Blha M., Cermanov M., Blha V., Blaek M., Mal J., irok O., Solichov D., Filip S., ehek V., Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia Therapeutic Apheresis and Dialysis 2007 11 1 9 15
24. Blha M., Krejsek J., Andrs C., Adhesive selectin molecules, MCP-1 and endotelin-1 during long-lasting LDL apheresis in familial hyperlipoproteinemia Therapeutic Apheresis and Dialysis 2005 9 A29
25. Blha M., Strasova A., Ungerman L., Significance of non-invasive cardiovascular examinations for the evaluation of extracorporeal LDL-cholesterol elimination efficacy Transfusion Medicine and Hemotherapy 2008 35, supplement 80
26. Blha M., Rencov E., Studnika J., Blha V., Mal J., Cyprianou G., Langrov H., Cascade filtration in the therapy of the dry form of age-related macular degeneration Therapeutic Apheresis and Dialysis 2009 13 5 453 454
27. Novkov L., Vlkov H., atnsk D., Sadlek P., Solichov D., Blha M., Blha V., Solich P., Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin Journal of Chromatography B 2009 877 22 2093 2103
28. Williams R. R., Hunt S. C., Schumacher M. C., Hegele R. A., Leppert M. F., Ludwig E. H., Hopkins P. N., Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics American Journal of Cardiology 1993 72 2 171 176
29. Samnek M., Urbanov Z., Cholesterol and triglyceride levels and their development from 2 to 17 years of age Casops Lkar Ceskch 1997 136 12 380 385
30. Sleator R. D., Hill C., Rational design of improved pharmabiotics Journal of Biomedicine and Biotechnology 2009 2009 7
31. Ye L.-H., Zhang H., Wu L.-Y., Zhang S., Qiu L. -Y., Li N., Zhang X., Zhang X. -Z., Shan C. -L., Zhang X. -D., Anti-Hepatitis B Virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV Journal of Biomedicine and Biotechnology 2009 2009 6
32. Karray-Chouayekh S., Trifa F., Khabir A., Boujelbane N., Sellami-Boudawara T., Daoud J., Frikha M., Gargouri A., Mokdad-Gargouri R., Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in tunisian patients with invasive breast carcinoma Journal of Biomedicine and Biotechnology 2009 2009 7
33. Iga A. M., Robertson J. H. P., Winslet M. C., Seifalian A. M., Clinical potential of quantum dots Journal of Biomedicine and Biotechnology 2007 2007 10
34. El Andaloussi A., Bilhou-Nabera C., New complex chromosomal translocation in chronic myeloid leukaemia: T(9;18;22)(q34;p11;q11) Journal of Biomedicine and Biotechnology 2007 2007 3
35. Stern R. H., Yang B.-B., Hounslow N. J., Macmahon M., Abel R. B., Olson S. C., Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atovarstatin, an HMG-CoA reductase inhibitor Journal of Clinical Pharmacology 2000 40 6 616 623
36. Rossi J., Jonak P., Rouleau L., Danielczak L., Tardif J.-C., Leask R. L., Differential response of endothelial cells to Simvastatin when conditioned with steady, non-reversing pulsatile or oscillating shear stress. Annals of Biomedical Engineering. In press
37. Heeschen C., Hamm C. W., Laufs U., Snapinn S., Bhm M., White H. D., Withdrawal of statins increases event rates in patients with acute coronary syndromes Circulation 2002 105 12 1446 1452
38. Wanahita N., Chen J., Bangalore S., Shah K., Rachko M., Coleman C. I., Schweitzer P., The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis. American Journal of Therapeutics. In press
39. Zoja C., Corna D., Gagliardini E., Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes which translates into full renoprotection. American Journal of Physiology. In press
40. Rosenson R. S., Tangney C. C., Antiatherothrombotic properties of statins: implications for cardiovascular event reduction Journal of the American Medical Association 1998 279 20 1643 1650
41. Goodman Gilman's, The Pharmacological Basis of Therapeutics 2006 11th New York, NY, USA McGraw-Hill
42. Sweetman S. C., Martindale: The Complete Drug Reference 2007 35th London, UK Pharmaceutical Press